Loading...

 

What is it about?

Follicular lymphoma is the second most diagnosed lymphoma in Western Europe. Significant advancements have considerably improved the survival of FL patients. However, 10-20% of these patients are refractory to standard treatments, and most of them will relapse. The treatment of follicular lymphoma patients with multiply relapsed or refractory disease represents an area of high-unmet needing new treatments with stronger efficacy. Chimeric antigen receptor (CAR)-T cell therapy targeting B-cell antigens, such as CD19 or CD20, is emerging as an efficacious treatment for R/R follicular lymphoma patients,

Featured Image

Why is it important?

This review article makes the point on the real possibility of T-CAR therapy on relapsed Follicular lymphomas, reporting updated and comprehensive scientific literature with critical comments, which can help the reader to attain a personal opinion.

Perspectives

GLSorry, your browser does not support inline SVG.

Utilization of heterologous standard cell preparation could increase the utilization of this therapy while improving the duration of remission obtained.

Prof. Giuseppe Leone
Universita Cattolica del Sacro Cuore

Read the Original

This page is a summary of: CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS, Mediterranean Journal of Hematology and Infectious Diseases, January 2024, Institute of Hematology, Catholic University,
DOI: 10.4084/mjhid.2024.012.
You can read the full text:

Read

Contributors

The following have contributed to this page